GSEP
BPMC

Golden State Equity Partners’s Blueprint Medicines BPMC Stock Holding History

Golden State Equity Partners’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,070
Closed -$201K – 256
2021
Q1 		$201K Hold
2,070
– – 0.11% 161
2020
Q4 		$232K Buy
+2,070
New +$218K 0.16% 146

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Golden State Equity Partners's BPMC Position: Q2 2021 in Review

Golden State Equity Partners sold out of Blueprint Medicines (BPMC) in Q2 2021, closing a stake of 2,070 shares — an estimated $201K sold.

Golden State Equity Partners first reported a position in BPMC in Q4 2020 and held it in 2 quarters. The position peaked at $232K in Q4 2020. 281 funds tracked by Wall St. Rank hold BPMC as of Q2 2021.

  • Golden State Equity Partners reported no remaining Blueprint Medicines position as of Q2 2021 after selling out during the quarter.
  • Golden State Equity Partners sold 2,070 Blueprint Medicines shares in Q2 2021, an estimated $201K.
  • Golden State Equity Partners first reported a position in Blueprint Medicines in Q4 2020 and held it in 2 quarters.
  • Golden State Equity Partners's Blueprint Medicines position peaked at $232K in Q4 2020.
  • 281 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2021.

Based on Golden State Equity Partners's 13F filing for Q2 2021, filed 12 Aug 2021.